Skip to main content Skip to main navigation menu Skip to site footer

Topical nonsteroidal anti-inflammatory drugs in the prevention of pseudophakic cystoid macular edema following phacoemulsification: A systematic review


Introduction: The goal of surgeons to avoid Pseudophakic Cystoid Macular Edema (PCMO) has led to the widespread use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) after cataract surgery, although current research into the best anti-inflammatory drugs to avoid PCMO is still underway. This review aimed to determine the efficacy of topical NSAIDs in preventing PCMO following phacoemulsification.

Methods: This systematic review was built on the recommended reporting items for systematic reviews and meta-analyses (PRISMA) and PICO criteria for papers during the previous 10 years. The keywords was searched by Boolean operator: “NSAIDs” AND “Prevention” AND “Cystoid Macular Edema” AND “Optical Coherence Tomography” AND “Phacoemulsification”. According to  STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist, the quality of each chosen article was evaluated.

Results: We have selected five articles of prospective cohort studies, which involved 756 patients whom received topical NSAIDs (Nepafenac 0.3%, Ketorolac Tromethamine 0.4%Nepafenac 0.1%, , and Diclofenac 0.1%) in treatment group and 700 patients received Placebo (Artificial tears) in control group. There was significant difference of central macular thickness based on OCT results between NSAIDs and control (placebo) group after uneventful phacoemulsification. Additionally, NSAIDs used as a preventative before phacoemulsification procedure exhibited a significantly reduced rise in central foveal thickness compared to placebo. There were changes of central macular thicknes postoperatively, and were significantly different from preoperative.

Conclusion: It has been demonstrated that topical NSAIDs successfully lower the incidence of Pseudophakic Cystoid Macular Edema following phacoemulsification.


  1. Nizami AA, Gulani AC. Cataract [Internet]. Vol. 1, StatPearls. 2022 [cited 2022 Aug 16]. p. 4–5. Available from:
  2. Hashemi H, Pakzad R, Yekta A, Aghamirsalim M, Pakbin M, Ramin S, et al. Global and Regional Prevalence of Age-related Cataract: A Comprehensive Systematic Review and Meta-analysis. Eye (Basingstoke). 2020 Aug 1;34(8):1357–70.
  3. N Congdon JVBK. Prevalence of Cataract and Pseudophakia/Aphakia among Adults in the United States. Arch Ophthalmol. 2004 Apr 2;4:1–2.
  4. Lee GI, Lim DH, Chi SA. Incidence and Characteristics of Intraocular Lens Dislocation after Phacoemulsification: An Eight-Year, Nationwide, Population-Based Study. National Libary of Medicine. 2021 Aug 26;17(10):2–3.
  5. Grzybowski A, Zemaitiene R, Mikalauskiene L. Post-cataract Cystoid Macular Oedema Prevention – Update 2019. European Ophthalmic Review [Internet]. 2019;13(1):37. Available from:
  6. Grzybowski A, Sikorski BL, Ascaso FJ, Huerva V. Pseudophakic Cystoid Macular Edema: Update 2016. Vol. 11, Clinical Interventions in Aging. Dove Medical Press Ltd.; 2016. p. 1221–9.
  7. Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. Cystoid Macular Edema after Phacoemulsification: Relationship to Blood-aqueous Barrier Damage and Visual Acuity. J Cataract Refract Surg. 1999;25:1492–7.
  8. Seth I, Bulloch G, Tan A, Thornell E, Agarwal S. Incidence of Pseudophakic Cystoid Macular Oedema Post-Cataract Surgery in Illawarra Shoalhaven Local Health District, Australia. Biomedicine Hub. 2022 Jan 18;7(1):1–10.
  9. Chung YR, Kim YH, Lee SY, Byeon HE, Lee K. Insights into the Pathogenesis of Cystoid Macular Edema: Leukostasis and Related Cytokines. International Journal of Ophthalmology. 2019;12(7):1202–8.
  10. Vukicevic M, Gin T, Al-Qureshi S. Prevalence of Optical Coherence Tomography-Diagnosed Postoperative Cystoid Macular Oedema in Patients following Uncomplicated Phaco-emulsification Cataract Surgery. Clinical and Experimental Ophthalmology. 2012 Apr;40(3):282–7.
  11. Jain S, Athale A, Chaurasia PK, Bijlani N. Incidence of Cystoid Macular Edema in Patients after Cataract Surgery at a Tertiary Care Centre in Central India. International Journal of Contemporary Medical Research [Internet]. 2020;7(9):11–2. Available from:
  12. Ching HY, Wong AC, Wong CC, Woo DC, Chan CW. Cystoid Macular Oedema and Changes in Retinal Thickness after Phacoemulsification with Optical Coherence Tomography. Eye. 2006;20(3):297–303.
  13. Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC. Risk Factors and Incidence of Macular Edema after Cataract Surgery A Database Study of 81984 Eyes. Ophthalmology. 2016;123(2):316–23.
  14. Kessel L, Tendal B, Jørgensen KJ, Erngaard D, Flesner P, Andresen JL, et al. Post-Cataract Prevention of Inflammation and Macular Edema by Steroid and Nonsteroidal Anti-inflammatory Eye Drops: A Systematic Review. Ophthalmology. 2014 Oct 1;121(10):1915–24.
  15. McCafferty S, Harris A, Kew C, Kassm T, Lane L, Levine J, et al. Pseudophakic Cystoid Macular Edema Prevention and Risk Factors; Prospective Study with Adjunctive Once Daily Topical Nepafenac 0.3% versus Placebo. BMC Ophthalmology. 2017 Feb 20;17(1).
  16. Tzelikis PF, Morato CS, Neves NT, Hida WT, Alves MR. Intraindividual Comparison of Nepafenac 0.3% for the Prevention of Macular Edema after Phacoemulsification. Journal of Cataract and Refractive Surgery. 2018 Apr 1;44(4):440–6.
  17. Alnagdy AA, Abouelkheir HY, El-Khouly SE, Tarshouby SM. Impact of Topical Nonsteroidal Anti-inflammatory Drugs in Prevention of Macular Edema following Cataract Surgery in Diabetic Patients. International Journal of Ophthalmology. 2018;11(4):616–22.
  18. Tzelikis PF, Vieira M, Hida WT, Motta AF, Nakano CT, Nakano EM, et al. Comparison of Ketorolac 0.4% and Nepafenac 0.1% for the Prevention of Cystoid Macular Oedema after Phacoemulsification: Prospective Placebo-controlled Randomised Study. British Journal of Ophthalmology. 2015 May 1;99(5):654–8.
  19. Medić A, Jukić T, Matas A, Vukojević K, Sapunar A, Znaor L. Effect of Preoperative Topical Diclofenac on Intraocular Interleukin-12 Concentration and Macular Edema after Cataract Surgery in Patients with Diabetic Retinopathy: A Randomized Controlled Trial. Croatian Medical Journal. 2017;58(1):49–55.
  20. Grzybowski A, Kanclerz P. The Role of Steroids and NSAIDs in Prevention and Treatment of Postsurgical Cystoid Macular Edema. Current Pharmaceutical Design. 2019 Mar 22;24(41):4896–902.
  21. Giarmoukakis AK, Blazaki S v., Bontzos GC, Plaka AD, Seliniotakis KN, Ioannidi LD, et al. Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema. Therapeutics and Clinical Risk Management. 2020;16:1067–74.
  22. K K, R B, S S, K J, A W. Cataract Surgery in Patients with Diabetic Retinopathy: Visual Outcome, Progression of Diabetic Retinopathy, and Incidence of Diabetic Macular Oedema. Graefes Arch Clin Exp Ophthalmol . 2002;240(9):735–8.
  23. Bardoloi N, Sarkar S, Burgute PS, Deb AK, Dholkawala R, Aggarwal P, et al. Comparison of Once Daily Dose of 0.3% Nepafenac Alone and Three Times Dose of 0.1% Nepafenac Alone in Pain and Inflammation Control after Phacoemulsification. Indian Journal of Ophthalmology. 2022 Mar 1;70(3):807–12.

How to Cite

Arista Dewi, N. P. A. P. ., & Pemayun, C. I. D. . (2023). Topical nonsteroidal anti-inflammatory drugs in the prevention of pseudophakic cystoid macular edema following phacoemulsification: A systematic review. Bali Medical Journal, 12(2), 1696–1702.




Search Panel

Ni Putu Ayu Pande Arista Dewi
Google Scholar
BMJ Journal

Cokorda Istri Dewiyani Pemayun
Google Scholar
BMJ Journal